|
G |
ACTA1 |
actin alpha 1, skeletal muscle |
increases expression |
ISO |
Norepinephrine results in increased expression of ACTA1 mRNA |
CTD |
PMID:17592507 |
|
NCBI chr 1:229,431,245...229,434,094
Ensembl chr 1:229,430,365...229,434,104
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of ACTA2 mRNA [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
ADA |
adenosine deaminase |
multiple interactions decreases response to substance |
ISO |
[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine] |
CTD |
PMID:7949234 PMID:17428236 |
|
NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
affects binding multiple interactions increases activity affects expression affects response to substance |
EXP ISO |
Norepinephrine binds to ADRA1A protein [Norepinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1A protein; Norepinephrine inhibits the reaction [ADRA1A protein binds to Prazosin] Norepinephrine results in increased activity of ADRA1A protein 5-methylurapidil inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; [chlorethylclonidine co-treated with Phenoxybenzamine] inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; BMY 7378 inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; chlorethylclonidine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Phenoxybenzamine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Spiperone inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein] Norepinephrine affects the expression of ADRA1A protein ADRA1A protein affects the susceptibility to Norepinephrine |
CTD |
PMID:8183249 PMID:10416824 PMID:12417256 PMID:20030735 |
|
NCBI chr 8:26,748,150...26,867,379
Ensembl chr 8:26,748,150...26,867,278
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
multiple interactions |
EXP |
[Norepinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1B protein; Norepinephrine inhibits the reaction [ADRA1B protein binds to Prazosin] |
CTD |
PMID:20030735 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
ADRA1D |
adrenoceptor alpha 1D |
affects binding multiple interactions affects response to substance |
EXP ISO |
Norepinephrine binds to ADRA1D protein [Norepinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1D protein; Norepinephrine inhibits the reaction [ADRA1D protein binds to Prazosin] ADRA1D affects the susceptibility to Norepinephrine Norepinephrine binds to and affects the activity of ADRA1D protein |
CTD |
PMID:8183249 PMID:9639061 PMID:11901185 PMID:15493479 PMID:20030735 |
|
NCBI chr20:4,220,630...4,249,287
Ensembl chr20:4,220,630...4,249,287
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
affects secretion multiple interactions affects abundance affects binding |
ISO EXP |
ADRA2A protein affects the secretion of Norepinephrine [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine ADRA2A protein affects the abundance of Norepinephrine 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; [Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Norepinephrine binds to and results in increased activity of ADRA2A protein; Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein] Norepinephrine binds to ADRA2A protein [BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]] |
CTD |
PMID:10336518 PMID:10742289 PMID:11312645 PMID:20030735 PMID:20083574 |
|
NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907
|
|
G |
ADRA2B |
adrenoceptor alpha 2B |
multiple interactions |
EXP |
[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2B protein; Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan] |
CTD |
PMID:20030735 |
|
NCBI chr 2:96,112,876...96,116,571
Ensembl chr 2:96,112,876...96,116,571
|
|
G |
ADRA2C |
adrenoceptor alpha 2C |
affects binding multiple interactions |
ISO EXP |
Norepinephrine binds to ADRA2C protein [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine [Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2C protein; Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan] |
CTD |
PMID:10336518 PMID:20030735 PMID:20083574 |
|
NCBI chr 4:3,766,385...3,768,526
Ensembl chr 4:3,766,348...3,768,526
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
multiple interactions |
EXP ISO |
[Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB1 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]; Propranolol inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRB1 protein] [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Norepinephrine |
CTD |
PMID:8096834 PMID:10344530 PMID:12010770 PMID:14730417 PMID:17200720 |
|
NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions affects binding |
ISO EXP |
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine] [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB2 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]; Propranolol inhibits the reaction [Norepinephrine binds to ADRB2 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine binds to ADRB2 protein] |
CTD |
PMID:7969507 PMID:10344530 PMID:14730417 PMID:24929186 |
|
NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623
|
|
G |
ADRB3 |
adrenoceptor beta 3 |
multiple interactions increases activity |
EXP ISO |
[Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB3 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein] Norepinephrine results in increased activity of ADRB3 protein 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Norepinephrine results in increased activity of ADRB3 protein]; Norepinephrine binds to and results in increased activity of ADRB3 protein |
CTD |
PMID:1682311 PMID:7815362 PMID:8569714 PMID:10344530 PMID:14730417 PMID:17622774 More...
|
|
NCBI chr 8:37,962,990...37,966,599
Ensembl chr 8:37,962,990...37,966,599
|
|
G |
AGT |
angiotensinogen |
increases abundance affects abundance multiple interactions |
ISO |
AGT protein results in increased abundance of Norepinephrine Norepinephrine affects the abundance of AGT protein carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Losartan inhibits the reaction [AGT protein results in increased abundance of Norepinephrine] |
CTD |
PMID:614752 PMID:15741261 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AGTR2 |
angiotensin II receptor type 2 |
affects response to substance |
ISO |
AGTR2 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:11714657 |
|
NCBI chr X:116,170,744...116,174,974
Ensembl chr X:116,170,744...116,174,974
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of AKT1 protein modified form |
CTD |
PMID:16338971 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ANXA1 |
annexin A1 |
multiple interactions |
ISO |
ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein] |
CTD |
PMID:16835395 |
|
NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393
|
|
G |
AQP2 |
aquaporin 2 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of AQP2 protein |
CTD |
PMID:16788141 |
|
NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
affects abundance decreases expression |
ISO |
ATP2A2 protein affects the abundance of Norepinephrine Norepinephrine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17592507 PMID:19328205 |
|
NCBI chr12:110,280,616...110,351,093
Ensembl chr12:110,280,756...110,351,093
|
|
G |
AVP |
arginine vasopressin |
multiple interactions |
ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA |
CTD |
PMID:11742803 |
|
NCBI chr20:3,082,556...3,084,724
Ensembl chr20:3,082,556...3,084,724
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of BAX protein] Norepinephrine results in increased expression of BAX mRNA; Norepinephrine results in increased expression of BAX protein |
CTD |
PMID:18675472 PMID:20374255 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein] |
CTD |
PMID:14732211 PMID:17041759 PMID:20374255 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:18675472 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BDKRB2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 affects the susceptibility to Norepinephrine |
CTD |
PMID:12105144 |
|
NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166
|
|
G |
C5AR2 |
complement C5a receptor 2 |
increases expression |
ISO |
Norepinephrine results in increased expression of C5AR2 mRNA; Norepinephrine results in increased expression of C5AR2 protein |
CTD |
PMID:15715664 |
|
NCBI chr19:47,332,175...47,347,329
Ensembl chr19:47,332,175...47,347,329
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
affects response to substance increases abundance multiple interactions |
ISO |
CALCA protein affects the susceptibility to Norepinephrine CALCA protein results in increased abundance of Norepinephrine Propranolol promotes the reaction [CALCA protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:8058111 PMID:18055875 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CALY |
calcyon neuron specific vesicular protein |
increases secretion |
EXP |
CALY protein results in increased secretion of Norepinephrine |
CTD |
PMID:30753204 |
|
NCBI chr10:133,324,072...133,336,896
Ensembl chr10:133,324,072...133,336,935
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
multiple interactions increases cleavage |
ISO |
CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form] |
CTD |
PMID:16338971 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP2 |
caspase 2 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein] |
CTD |
PMID:14732211 PMID:15158148 PMID:17041759 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
EXP ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein Norepinephrine results in increased activity of CASP3 protein Norepinephrine results in increased cleavage of CASP3 protein Norepinephrine results in increased expression of CASP3 protein Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of CASP3 protein]; Norepinephrine inhibits the reaction [Okadaic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:11099166 PMID:14732211 PMID:15158148 PMID:16338971 PMID:17041759 PMID:17136323 PMID:18675472 PMID:20374255 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP6 |
caspase 6 |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein] |
CTD |
PMID:14732211 PMID:15158148 |
|
NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein |
CTD |
PMID:17136323 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
affects activity |
ISO |
Norepinephrine affects the activity of CASP8 protein |
CTD |
PMID:25437044 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions affects activity increases cleavage increases activity |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein] Norepinephrine affects the activity of CASP9 protein Norepinephrine results in increased cleavage of CASP9 protein |
CTD |
PMID:14732211 PMID:15158148 PMID:16338971 PMID:25437044 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form] |
CTD |
PMID:16338971 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Norepinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]; Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]] |
CTD |
PMID:9863660 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases secretion multiple interactions |
EXP |
Norepinephrine results in increased secretion of CCL5 protein Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CCL5 protein] |
CTD |
PMID:16782692 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCN1 |
cellular communication network factor 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of CCN1 mRNA |
CTD |
PMID:15117851 |
|
NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589
|
|
G |
CNR1 |
cannabinoid receptor 1 |
affects expression |
EXP |
Norepinephrine affects the expression of CNR1 mRNA |
CTD |
PMID:29650773 |
|
NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO |
carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:10722803 PMID:14577597 PMID:19575289 PMID:34609854 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of COL3A1 mRNA [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:10722803 PMID:14577597 PMID:34609854 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
COMT |
catechol-O-methyltransferase |
multiple interactions increases methylation |
EXP |
[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine COMT protein results in increased methylation of Norepinephrine |
CTD |
PMID:11160877 PMID:11248589 |
|
NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,371...19,969,975
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Norepinephrine results in decreased expression of CPT1A mRNA |
CTD |
PMID:19109942 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CREM |
cAMP responsive element modulator |
increases expression |
ISO |
Norepinephrine results in increased expression of CREM mRNA |
CTD |
PMID:11171092 |
|
NCBI chr10:35,126,846...35,212,958
Ensembl chr10:35,126,791...35,212,958
|
|
G |
CRH |
corticotropin releasing hormone |
multiple interactions increases abundance |
ISO |
corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Norepinephrine]; Norepinephrine affects the expression of and affects the secretion of CRH protein; Propranolol affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Yohimbine affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein] CRH results in increased abundance of Norepinephrine |
CTD |
PMID:1320258 PMID:3497798 |
|
NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
|
|
G |
CRHR1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine] |
CTD |
PMID:24398105 |
|
NCBI chr17:45,784,320...45,835,828
Ensembl chr17:45,784,277...45,835,828
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Norepinephrine results in increased secretion of CXCL8 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CXCL8 protein] |
CTD |
PMID:16782692 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYCS |
cytochrome c, somatic |
affects localization increases localization |
ISO |
Norepinephrine affects the localization of CYCS protein Norepinephrine results in increased localization of CYCS protein |
CTD |
PMID:16338971 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
DBH |
dopamine beta-hydroxylase |
affects abundance increases abundance decreases abundance |
ISO |
DBH gene polymorphism affects the abundance of Norepinephrine DBH protein results in increased abundance of Norepinephrine DBH mutant form results in decreased abundance of Norepinephrine |
CTD |
PMID:15148402 PMID:16163519 PMID:18329701 |
|
NCBI chr 9:133,636,363...133,659,329
Ensembl chr 9:133,636,363...133,659,329
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
ISO |
Norepinephrine results in increased expression of DDIT3 mRNA; Norepinephrine results in increased expression of DDIT3 protein |
CTD |
PMID:16338971 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DRD1 |
dopamine receptor D1 |
multiple interactions |
ISO |
Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 protein] |
CTD |
PMID:20887679 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
EXP ISO |
[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; Sulpiride inhibits the reaction [[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium] Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 protein] |
CTD |
PMID:8032591 PMID:20887679 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions increases expression increases activity decreases secretion increases secretion |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; [EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; BQ 610 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine] Norepinephrine results in increased activity of EDN1 promoter |
CTD |
PMID:11435416 PMID:12184995 PMID:14759557 PMID:16023617 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDN3 |
endothelin 3 |
multiple interactions decreases secretion increases secretion |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; 2-aminoethoxydiphenyl borate inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; bisindolylmaleimide I inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine] |
CTD |
PMID:12184995 PMID:14759557 PMID:16023617 |
|
NCBI chr20:59,300,611...59,325,992
Ensembl chr20:59,300,443...59,325,992
|
|
G |
EDNRA |
endothelin receptor type A |
multiple interactions |
ISO |
[cyclo(Trp-Asp-Pro-Val-Leu) binds to and results in decreased activity of EDNRA protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EDNRB |
endothelin receptor type B |
multiple interactions |
ISO |
[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine |
CTD |
PMID:16023617 |
|
NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
|
|
G |
EFHD2 |
EF-hand domain family member D2 |
increases secretion |
ISO |
EFHD2 gene mutant form results in increased secretion of Norepinephrine |
CTD |
PMID:28397836 |
|
NCBI chr 1:15,409,888...15,430,339
Ensembl chr 1:15,409,888...15,430,339
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA |
CTD |
PMID:11742803 PMID:12632255 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form] |
CTD |
PMID:19168439 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EGR1 |
early growth response 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of EGR1 |
CTD |
PMID:7905536 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
ELK1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:11880281 |
|
NCBI chr X:47,635,520...47,650,604
Ensembl chr X:47,635,521...47,650,604
|
|
G |
ELOVL3 |
ELOVL fatty acid elongase 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA; Dactinomycin inhibits the reaction [Norepinephrine results in increased expression of ELOVL3 mRNA]; Norepinephrine results in increased expression of and results in decreased degradation of ELOVL3 mRNA; rosiglitazone promotes the reaction [[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:17726147 |
|
NCBI chr10:102,224,767...102,229,589
Ensembl chr10:102,226,299...102,229,589
|
|
G |
EPO |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Norepinephrine |
CTD |
PMID:14732207 |
|
NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA] |
CTD |
PMID:23114885 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FGF1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]; Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein] |
CTD |
PMID:11742803 PMID:15264218 |
|
NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]] |
CTD |
PMID:11742803 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FN1 |
fibronectin 1 |
multiple interactions |
EXP |
[Norepinephrine co-treated with Prazosin] results in decreased expression of FN1 protein; [Norepinephrine co-treated with Propranolol] results in increased expression of FN1 protein |
CTD |
PMID:11821714 |
|
NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073
|
|
G |
FNDC5 |
fibronectin type III domain containing 5 |
decreases abundance |
ISO |
FNDC5 protein results in decreased abundance of Norepinephrine |
CTD |
PMID:32165127 |
|
NCBI chr 1:32,862,268...32,872,484
Ensembl chr 1:32,862,268...32,872,482
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of FOS mRNA Norepinephrine results in increased expression of FOS; Norepinephrine results in increased expression of FOS mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of FOS mRNA] |
CTD |
PMID:7605896 PMID:7905536 PMID:12729908 PMID:19225867 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSB |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Norepinephrine results in increased expression of FOSB |
CTD |
PMID:7905536 |
|
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:19168439 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
increases activity multiple interactions increases expression |
ISO |
Norepinephrine results in increased activity of G6PD mRNA; Norepinephrine results in increased activity of G6PD protein Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of G6PD protein] Norepinephrine results in increased expression of G6PD mRNA |
CTD |
PMID:1378361 PMID:7605896 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GABPA |
GA binding protein transcription factor subunit alpha |
multiple interactions |
ISO |
[Progesterone co-treated with Norepinephrine] results in increased expression of GABPA mRNA |
CTD |
PMID:16954335 |
|
NCBI chr21:25,734,972...25,772,460
Ensembl chr21:25,734,570...25,772,460
|
|
G |
GK |
glycerol kinase |
increases activity increases expression |
ISO |
Norepinephrine results in increased activity of GK protein Norepinephrine results in increased expression of GK mRNA |
CTD |
PMID:12736183 |
|
NCBI chr X:30,653,423...30,731,462
Ensembl chr X:30,653,359...30,731,462
|
|
G |
GNAS |
GNAS complex locus |
multiple interactions |
EXP |
Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein] |
CTD |
PMID:17200720 |
|
NCBI chr20:58,839,748...58,911,192
Ensembl chr20:58,839,718...58,911,192
|
|
G |
HDC |
histidine decarboxylase |
affects abundance |
ISO |
HDC protein affects the abundance of Norepinephrine |
CTD |
PMID:12421355 |
|
NCBI chr15:50,241,947...50,265,726
Ensembl chr15:50,241,947...50,265,965
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
Propranolol inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:24929186 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Norepinephrine results in increased expression of HSPA5 mRNA; Norepinephrine results in increased expression of HSPA5 protein |
CTD |
PMID:16338971 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HTR2B |
5-hydroxytryptamine receptor 2B |
multiple interactions increases expression |
ISO |
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of HTR2B protein] |
CTD |
PMID:20374255 |
|
NCBI chr 2:231,108,230...231,125,042
Ensembl chr 2:231,108,230...231,125,042
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]] |
CTD |
PMID:23114885 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions decreases response to substance |
ISO |
Prazosin inhibits the reaction [IGF1 protein results in decreased susceptibility to Norepinephrine] |
CTD |
PMID:17184500 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IL1B |
interleukin 1 beta |
affects secretion increases expression multiple interactions |
ISO |
Norepinephrine affects the secretion of IL1B protein Norepinephrine results in increased expression of IL1B mRNA carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein] |
CTD |
PMID:8392517 PMID:10722803 PMID:16386803 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions increases expression increases activity decreases secretion |
EXP ISO |
Norepinephrine results in increased expression of and results in increased secretion of IL6 protein; sulforaphane inhibits the reaction [Norepinephrine results in increased expression of and results in increased secretion of IL6 protein] Norepinephrine results in increased expression of IL6 mRNA; Norepinephrine results in increased expression of IL6 protein Norepinephrine results in increased activity of IL6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] Norepinephrine results in decreased secretion of IL6 protein ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein] |
CTD |
PMID:8392517 PMID:10722803 PMID:11406463 PMID:12619890 PMID:14577597 PMID:16835395 PMID:18636164 More...
|
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
multiple interactions |
ISO |
INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP] |
CTD |
PMID:4306506 |
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases phosphorylation increases expression |
ISO |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of JUN mRNA] Norepinephrine results in increased expression of JUN; Norepinephrine results in increased expression of JUN mRNA |
CTD |
PMID:7905536 PMID:19225867 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
JUNB |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Norepinephrine results in increased expression of JUNB |
CTD |
PMID:7905536 |
|
NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315
|
|
G |
KCNMA1 |
potassium calcium-activated channel subfamily M alpha 1 |
affects response to substance |
ISO |
KCNMA1 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:22226998 |
|
NCBI chr10:76,869,602...77,637,808
Ensembl chr10:76,869,601...77,638,369
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein; Phenoxybenzamine inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Piperoxan inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Prazosin inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein] |
CTD |
PMID:3953791 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LPL |
lipoprotein lipase |
multiple interactions increases expression |
ISO |
Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA] |
CTD |
PMID:9032464 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
MAOA |
monoamine oxidase A |
increases metabolic processing increases abundance |
EXP ISO |
MAOA protein results in increased metabolism of Norepinephrine MAOA mutant form results in increased abundance of Norepinephrine |
CTD |
PMID:10647887 PMID:11834493 |
|
NCBI chr X:43,655,006...43,746,817
Ensembl chr X:43,654,907...43,746,817
|
|
G |
MAOB |
monoamine oxidase B |
increases abundance |
ISO |
MAOB mutant form results in increased abundance of Norepinephrine |
CTD |
PMID:11834493 |
|
NCBI chr X:43,766,610...43,882,450
Ensembl chr X:43,766,610...43,882,450
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein] Norepinephrine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Prazosin affects the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 PMID:17041759 PMID:20434527 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK10 |
mitogen-activated protein kinase 10 |
multiple interactions |
ISO |
MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:16949803 |
|
NCBI chr 4:86,010,405...86,594,074
Ensembl chr 4:85,990,007...86,594,625
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 PMID:17041759 PMID:20434527 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:17041759 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions affects response to substance |
ISO |
MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:16949803 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions increases expression increases activity |
ISO EXP |
Cromolyn Sodium inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Norepinephrine results in increased activity of and results in increased expression of MMP2 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased activity of MMP2 protein]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] |
CTD |
PMID:14577597 PMID:15326086 PMID:16864425 PMID:24929186 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions increases expression increases activity |
ISO EXP |
trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] Norepinephrine results in increased activity of MMP9 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; SR 11302 inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; tanshinone inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] |
CTD |
PMID:16864425 PMID:24929186 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
[EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA Norepinephrine results in increased expression of MYC |
CTD |
PMID:7605896 PMID:12632255 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
MYH6 |
myosin heavy chain 6 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of MYH6 mRNA |
CTD |
PMID:17592507 |
|
NCBI chr14:23,381,987...23,408,273
Ensembl chr14:23,381,982...23,408,273
|
|
G |
MYH7 |
myosin heavy chain 7 |
multiple interactions affects expression increases expression |
ISO |
Propranolol promotes the reaction [Norepinephrine results in increased expression of MYH7 mRNA] Norepinephrine affects the expression of MYH7 mRNA |
CTD |
PMID:17592507 PMID:25437044 |
|
NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660
|
|
G |
MYL1 |
myosin light chain 1 |
increases phosphorylation multiple interactions |
EXP ISO |
Norepinephrine results in increased phosphorylation of MYL1 protein PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein] chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein] |
CTD |
PMID:37963515 |
|
NCBI chr 2:210,290,150...210,315,174
Ensembl chr 2:210,290,150...210,315,174
|
|
G |
NFIL3 |
nuclear factor, interleukin 3 regulated |
increases expression |
ISO |
Norepinephrine results in increased expression of NFIL3 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr 9:91,409,045...91,483,497
Ensembl chr 9:91,409,045...91,423,832
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions affects localization |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein] |
CTD |
PMID:16782692 PMID:23114885 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NGF |
nerve growth factor |
decreases expression |
ISO |
Norepinephrine results in decreased expression of NGF mRNA; Norepinephrine results in decreased expression of NGF protein |
CTD |
PMID:8593794 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions affects response to substance |
ISO |
[GW 274150 results in decreased activity of NOS2 protein] which results in increased susceptibility to Norepinephrine; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] NOS2 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:16424707 PMID:19439816 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPPA |
natriuretic peptide A |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of NPPA mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Propranolol promotes the reaction [Norepinephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:9788975 PMID:10722803 PMID:14577597 PMID:15240149 PMID:16714034 PMID:17266992 PMID:17592507 More...
|
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NPPB |
natriuretic peptide B |
affects abundance decreases abundance |
EXP |
NPPB affects the abundance of Norepinephrine NPPB protein results in decreased abundance of Norepinephrine |
CTD |
PMID:16333235 PMID:20339970 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NPY |
neuropeptide Y |
affects response to substance |
EXP |
NPY protein affects the susceptibility to Norepinephrine |
CTD |
PMID:15003356 |
|
NCBI chr 7:24,284,190...24,291,862
Ensembl chr 7:24,284,188...24,291,862
|
|
G |
NRF1 |
nuclear respiratory factor 1 |
multiple interactions |
ISO |
[Estradiol co-treated with Norepinephrine] results in decreased expression of NRF1 mRNA |
CTD |
PMID:16954335 |
|
NCBI chr 7:129,611,720...129,757,076
Ensembl chr 7:129,611,720...129,757,082
|
|
G |
NTF3 |
neurotrophin 3 |
increases expression |
ISO |
Norepinephrine results in increased expression of NTF3 mRNA; Norepinephrine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr12:5,430,332...5,495,299
Ensembl chr12:5,432,108...5,521,536
|
|
G |
ODC1 |
ornithine decarboxylase 1 |
decreases activity |
ISO |
Norepinephrine results in decreased activity of ODC1 protein |
CTD |
PMID:1850525 |
|
NCBI chr 2:10,439,968...10,448,327
Ensembl chr 2:10,439,968...10,448,327
|
|
G |
OPRD1 |
opioid receptor delta 1 |
multiple interactions |
ISO |
[dextrallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 1:28,812,170...28,871,267
Ensembl chr 1:28,812,170...28,871,267
|
|
G |
OPRK1 |
opioid receptor kappa 1 |
multiple interactions |
ISO |
[dextrallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 8:53,225,724...53,251,637
Ensembl chr 8:53,225,724...53,251,637
|
|
G |
OPRM1 |
opioid receptor mu 1 |
multiple interactions |
ISO |
[dextrallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 6:154,010,496...154,246,867
Ensembl chr 6:154,010,496...154,246,867
|
|
G |
PER1 |
period circadian regulator 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of PER1 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr17:8,140,472...8,152,404
Ensembl chr17:8,140,472...8,156,506
|
|
G |
PER2 |
period circadian regulator 2 |
increases expression |
ISO |
Norepinephrine results in increased expression of PER2 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr 2:238,244,044...238,300,065
Ensembl chr 2:238,244,044...238,290,102
|
|
G |
PGD |
phosphogluconate dehydrogenase |
multiple interactions increases activity |
ISO |
carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein] |
CTD |
PMID:1378361 |
|
NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511
|
|
G |
PLCB1 |
phospholipase C beta 1 |
increases activity multiple interactions increases expression |
ISO |
Norepinephrine results in increased activity of PLCB1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA] Norepinephrine results in increased expression of PLCB1 mRNA; Norepinephrine results in increased expression of PLCB1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr20:8,132,266...8,884,900
Ensembl chr20:8,077,251...8,968,360
|
|
G |
PLCB3 |
phospholipase C beta 3 |
increases activity multiple interactions increases expression |
ISO |
Norepinephrine results in increased activity of PLCB3 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA] Norepinephrine results in increased expression of PLCB3 mRNA; Norepinephrine results in increased expression of PLCB3 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr11:64,251,530...64,269,452
Ensembl chr11:64,251,530...64,269,150
|
|
G |
PLCD1 |
phospholipase C delta 1 |
increases activity multiple interactions increases expression |
ISO |
Norepinephrine results in increased activity of PLCD1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA] Norepinephrine results in increased expression of PLCD1 mRNA; Norepinephrine results in increased expression of PLCD1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr 3:38,007,496...38,029,642
Ensembl chr 3:38,007,496...38,029,642
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
increases activity multiple interactions increases expression |
ISO |
Norepinephrine results in increased activity of PLCG1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein] Norepinephrine results in increased expression of PLCG1 mRNA; Norepinephrine results in increased expression of PLCG1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr20:41,137,543...41,177,626
Ensembl chr20:41,136,960...41,196,801
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression |
ISO |
Norepinephrine results in increased expression of PPARA mRNA |
CTD |
PMID:19109942 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases expression |
ISO |
Norepinephrine results in increased expression of PPARG mRNA |
CTD |
PMID:19109942 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO |
[Propranolol co-treated with Prazosin] inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA] Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 PMID:16954335 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPP1R12A |
protein phosphatase 1 regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP ISO |
Norepinephrine results in increased phosphorylation of PPP1R12A protein PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein] CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:37963515 |
|
NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
|
|
G |
PPP1R14A |
protein phosphatase 1 regulatory inhibitor subunit 14A |
multiple interactions increases phosphorylation |
ISO |
chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R14A protein] |
CTD |
PMID:37963515 |
|
NCBI chr19:38,251,237...38,256,374
Ensembl chr19:38,251,237...38,256,532
|
|
G |
PRKD1 |
protein kinase D1 |
multiple interactions increases phosphorylation |
ISO EXP |
CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKD1 protein] PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:37963515 |
|
NCBI chr14:29,576,479...29,927,847
Ensembl chr14:29,576,479...30,191,898
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[Estradiol co-treated with Norepinephrine] results in decreased expression of PTEN mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of PTEN mRNA; Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PTEN mRNA] |
CTD |
PMID:16954335 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
REL |
REL proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of REL protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of REL protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of REL protein]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]] |
CTD |
PMID:23114885 |
|
NCBI chr 2:60,881,574...60,931,612
Ensembl chr 2:60,881,491...60,931,612
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine affects the localization of RELA protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of RELA protein]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of RELA protein] |
CTD |
PMID:16782692 PMID:23114885 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Norepinephrine results in increased expression of S100A8 mRNA; Norepinephrine results in increased expression of S100A8 protein |
CTD |
PMID:16677282 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Norepinephrine results in increased expression of S100A9 mRNA; Norepinephrine results in increased expression of S100A9 protein |
CTD |
PMID:16677282 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
S100B |
S100 calcium binding protein B |
increases expression affects response to substance |
EXP |
Norepinephrine results in increased expression of S100B mRNA; Norepinephrine results in increased expression of S100B protein S100B protein affects the susceptibility to Norepinephrine |
CTD |
PMID:9788975 |
|
NCBI chr21:46,598,604...46,605,082
Ensembl chr21:46,598,604...46,605,208
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
ISO |
Norepinephrine results in increased expression of SCD1 mRNA |
CTD |
PMID:22413010 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SERPINE1 |
serpin family E member 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:17429342 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SERPINH1 |
serpin family H member 1 |
multiple interactions increases expression |
ISO |
carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein] Norepinephrine results in increased expression of SERPINH1 mRNA; Norepinephrine results in increased expression of SERPINH1 protein |
CTD |
PMID:10722803 |
|
NCBI chr11:75,562,253...75,572,783
Ensembl chr11:75,562,056...75,572,783
|
|
G |
SHC1 |
SHC adaptor protein 1 |
multiple interactions increases phosphorylation |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; Prazosin inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; U 0126 inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form] |
CTD |
PMID:19168439 |
|
NCBI chr 1:154,962,298...154,974,376
Ensembl chr 1:154,962,298...154,974,395
|
|
G |
SLC12A1 |
solute carrier family 12 member 1 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of SLC12A1 protein |
CTD |
PMID:16788141 |
|
NCBI chr15:48,206,302...48,304,078
Ensembl chr15:48,178,438...48,304,078
|
|
G |
SLC14A2 |
solute carrier family 14 member 2 |
decreases expression |
ISO |
Norepinephrine results in decreased expression of SLC14A2 protein |
CTD |
PMID:16788141 |
|
NCBI chr18:45,167,963...45,683,688
Ensembl chr18:45,212,995...45,683,688
|
|
G |
SLC18A1 |
solute carrier family 18 member A1 |
multiple interactions |
EXP |
Norepinephrine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] |
CTD |
PMID:8245983 |
|
NCBI chr 8:20,144,855...20,183,136
Ensembl chr 8:20,144,855...20,183,206
|
|
G |
SLC18A2 |
solute carrier family 18 member A2 |
multiple interactions decreases activity affects binding |
ISO EXP |
Norepinephrine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin] Norepinephrine results in decreased activity of SLC18A2 protein Norepinephrine binds to SLC18A2 protein |
CTD |
PMID:1438304 PMID:7912402 PMID:15475732 |
|
NCBI chr10:117,241,114...117,279,430
Ensembl chr10:117,241,093...117,279,430
|
|
G |
SLC22A3 |
solute carrier family 22 member 3 |
increases uptake multiple interactions |
EXP ISO |
SLC22A3 protein results in increased uptake of Norepinephrine Norepinephrine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:9830022 PMID:20858707 |
|
NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577
|
|
G |
SLC29A4 |
solute carrier family 29 member 4 |
increases uptake |
EXP |
SLC29A4 protein results in increased uptake of Norepinephrine |
CTD |
PMID:20858707 |
|
NCBI chr 7:5,282,943...5,306,912
Ensembl chr 7:5,274,369...5,306,912
|
|
G |
SLC6A2 |
solute carrier family 6 member 2 |
multiple interactions increases uptake decreases expression decreases uptake decreases activity |
EXP ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased uptake of Norepinephrine]; Norepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]; SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] [Cullen corylifolium extract results in decreased activity of SLC6A2 protein] which results in decreased uptake of Norepinephrine; Norepinephrine affects the localization of and affects the metabolism of SLC6A2 protein [Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine; Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; Lidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; tricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] Norepinephrine results in decreased expression of SLC6A2 protein SLC6A2 mutant form results in decreased uptake of Norepinephrine Norepinephrine results in decreased activity of SLC6A2 protein |
CTD |
PMID:11082428 PMID:11458707 PMID:16338971 PMID:16725121 PMID:17234900 PMID:17555897 PMID:30776375 More...
|
|
NCBI chr16:55,655,988...55,706,192
Ensembl chr16:55,655,988...55,707,645
|
|
G |
SLC6A3 |
solute carrier family 6 member 3 |
multiple interactions increases uptake |
EXP |
SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] SLC6A3 protein results in increased uptake of Norepinephrine |
CTD |
PMID:17234900 PMID:17250655 |
|
NCBI chr 5:1,392,794...1,445,440
Ensembl chr 5:1,392,794...1,445,440
|
|
G |
SLC6A4 |
solute carrier family 6 member 4 |
multiple interactions |
EXP |
SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr17:30,194,319...30,235,697
Ensembl chr17:30,194,319...30,236,002
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
increases expression |
ISO |
Norepinephrine results in increased expression of SLC8A1 mRNA; Norepinephrine results in increased expression of SLC8A1 protein |
CTD |
PMID:11179087 |
|
NCBI chr 2:40,097,270...40,512,435
Ensembl chr 2:40,097,270...40,611,053
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression increases expression multiple interactions |
ISO EXP |
Norepinephrine results in decreased expression of SOD2 protein Norepinephrine results in increased expression of SOD2 mRNA Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA] SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein] |
CTD |
PMID:19168439 PMID:23114885 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
increases phosphorylation multiple interactions |
ISO |
Norepinephrine results in increased phosphorylation of STAT3 protein [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]; Carnosine inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34609854 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
SULT1A3 |
sulfotransferase family 1A member 3 |
increases sulfation |
EXP |
SULT1A3 protein results in increased sulfation of Norepinephrine |
CTD |
PMID:11181495 |
|
NCBI chr16:30,199,255...30,204,310
Ensembl chr16:30,199,228...30,204,310
|
|
G |
TAAR1 |
trace amine associated receptor 1 |
multiple interactions |
EXP |
SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr 6:132,643,312...132,659,182
Ensembl chr 6:132,643,312...132,659,182
|
|
G |
TBXA2R |
thromboxane A2 receptor |
multiple interactions |
ISO |
[SQ 29548 binds to and results in decreased activity of TBXA2R protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr19:3,594,507...3,606,875
Ensembl chr19:3,594,507...3,606,875
|
|
G |
TFAM |
transcription factor A, mitochondrial |
multiple interactions |
ISO |
[Estradiol co-treated with Norepinephrine] results in decreased expression of TFAM mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of TFAM mRNA |
CTD |
PMID:16954335 |
|
NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions increases expression |
ISO |
Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:15326086 PMID:19575289 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFB2 |
transforming growth factor beta 2 |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of TGFB2 mRNA; Norepinephrine results in increased expression of TGFB2 protein Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619
|
|
G |
TGFB3 |
transforming growth factor beta 3 |
increases expression multiple interactions |
ISO |
Norepinephrine results in increased expression of TGFB3 mRNA Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB3 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011
|
|
G |
TH |
tyrosine hydroxylase |
multiple interactions increases chemical synthesis |
ISO |
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine TH protein results in increased chemical synthesis of Norepinephrine |
CTD |
PMID:9822156 PMID:19067675 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
THY1 |
Thy-1 cell surface antigen |
decreases expression multiple interactions |
ISO |
Norepinephrine results in decreased expression of THY1 Propranolol inhibits the reaction [Norepinephrine results in decreased expression of THY1] |
CTD |
PMID:7558147 |
|
NCBI chr11:119,415,476...119,424,985
Ensembl chr11:119,415,476...119,424,985
|
|
G |
TIMP2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions increases expression |
ISO |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA] |
CTD |
PMID:14577597 PMID:15326086 |
|
NCBI chr17:78,852,977...78,925,387
Ensembl chr17:78,852,977...78,925,387
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Norepinephrine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein] Norepinephrine results in increased expression of TNF mRNA |
CTD |
PMID:8392517 PMID:15081246 PMID:15158148 PMID:25437044 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
UCP1 |
uncoupling protein 1 |
multiple interactions increases expression |
ISO |
[Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 mRNA; [Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 protein; AG 1879 promotes the reaction [Norepinephrine results in increased expression of UCP1 mRNA] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA |
CTD |
PMID:10465291 PMID:10788502 PMID:11742803 PMID:29910772 PMID:31048375 |
|
NCBI chr 4:140,559,431...140,568,961
Ensembl chr 4:140,559,431...140,568,961
|
|
G |
UCP2 |
uncoupling protein 2 |
increases expression |
ISO |
Norepinephrine results in increased expression of UCP2 mRNA |
CTD |
PMID:8593794 PMID:12588052 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843
|
|
G |
USF1 |
upstream transcription factor 1 |
multiple interactions |
EXP |
USF1 gene polymorphism promotes the reaction [Norepinephrine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Norepinephrine results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr 1:161,039,251...161,045,977
Ensembl chr 1:161,039,251...161,045,977
|
|
G |
VDR |
vitamin D receptor |
increases abundance |
EXP |
VDR protein results in increased abundance of Norepinephrine |
CTD |
PMID:27450565 |
|
NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[Cobalt co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Norepinephrine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of VEGFA mRNA; AG 1879 inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
XBP1 |
X-box binding protein 1 |
affects localization |
ISO |
Norepinephrine affects the localization of XBP1 protein |
CTD |
PMID:16338971 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|